Relapse and Long-Acting Injectable Risperidone: A 1-Year Mirror Image Study with a National Claims Database in Taiwan

Knapp, 2000, Schizophrenia costs and treatment cost-effectiveness, Acta Psychiatr Scand, 102, S15, 10.1046/j.1467-0658.2001.00137.x-i1 Altamura, 2007, Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment, Int Clin Psychopharmacol, 22, 249, 10.1097/YIC.0b013e3280de2c7f Shepherd, 1989, The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics, Psychol Med Monogr Suppl, 15, 1, 10.1017/S026418010000059X Wyatt, 1995, Early intervention for schizophrenia: can the course of the illness be altered?, Biol Psychiatry, 38, 1, 10.1016/0006-3223(95)00191-I Meisenzahl, 2008, Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study, Schizophr Res, 104, 44, 10.1016/j.schres.2008.06.023 Cramer, 1998, Compliance with medication regimens for mental and physical disorders, Psychiatr Serv, 49, 196, 10.1176/ps.49.2.196 Dolder, 2002, Antipsychotic medication adherence: is there a difference between typical and atypical agents?, Am J Psychiatry, 159, 103, 10.1176/appi.ajp.159.1.103 Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N Engl J Med, 353, 1209, 10.1056/NEJMoa051688 Davis, 2003, Choice of maintenance medication for schizophrenia, J Clin Psychiatry, 64, S1624 Davis, 1993, Dose response of prophylactic antipsychotics, J Clin Psychiatry, 54, S24 Schooler, 2003, Relapse and rehospitalization: comparing oral and depot antipsychotics, J Clin Psychiatry, 64, S1614 Kane, 2003, Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies, J Clin Psychiatry, 64, S1634 Denham, 1971, The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients, Acta Psychiatr Scand, 47, 420, 10.1111/j.1600-0447.1971.tb03699.x Freedman, 2003, Schizophrenia, N Engl J Med, 349, 1738, 10.1056/NEJMra035458 Mueser, 2004, Schizophrenia, Lancet, 363, 2063, 10.1016/S0140-6736(04)16458-1 Schultz, 1999, Schizophrenia, Lancet, 353, 1425, 10.1016/S0140-6736(98)07549-7 Heeg, 2008, The cost-effectiveness of atypicals in the UK, Value Health, 11, 1007, 10.1111/j.1524-4733.2008.00344.x Lecomte, 2000, A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium, Value Health, 3, 1, 10.1046/j.1524-4733.2000.31001.x Niaz, 2007, Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care, Acta Psychiatr Scand, 116, 36, 10.1111/j.1600-0447.2006.00980.x Chang, 2009, Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan, J Clin Psychiatry, 70, 141, 10.4088/JCP.08l04447 Marriott, 1976, A mirror image out-patient study at a depot phenothiazine clinic, Aust N Z J Psychiatry, 10, 163, 10.3109/00048677609159495 Polonowita, 1976, Fluphenazine decanoate maintenance in schizophrenia: a retrospective study, N Z Med J, 83, 316 Lane, 2000, Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels, J Clin Psychiatry, 61, 209, 10.4088/JCP.v61n0311 Burns, 2007, Hospitalisation as an outcome measure in schizophrenia, Br J Psychiatry, 191, S37, 10.1192/bjp.191.50.s37